文献速递自身炎症与 IgG4 相关病血管炎其他结缔组织病

基于基因组学的系统性自身炎症性疾病识别:两个人群生物样本库回顾性队列研究

Genomic ascertainment of systemic autoinflammatory diseases: a retrospective cohort study in two population-based biobanks.
PubMed 文献 · Lancet Rheumatol · 2026-10-13

该研究采用基因组优先策略,在两个人群生物样本库(Geisinger MyCode 与 UK Biobank)中分析 28 个基因的致病/可能致病变异,共纳入 640 092 人。共识别 159 例携带者,合并患病率约 1/4026;总体外显率 51%,但仅 1 例有自身炎症性疾病诊断记录,提示疾病识别存在显著缺口。

要点

  • 单基因自身炎症性疾病患病率约 1/4026,高于既往认识。
  • 携带者总体外显率 51%,Geisinger 为 79%,UK Biobank 为 32%。
  • 仅 1 例携带者有明确自身炎症性疾病诊断,识别缺口显著。

核心结论

  • 单基因系统性自身炎症性疾病比目前认识的更常见,但绝大多数携带致病或可能致病变异者缺乏明确诊断,存在显著识别缺口。

研究设计与样本

  • 回顾性队列研究,采用基因组优先方法,整合全外显子测序与电子健康记录,数据来自 Geisinger MyCode 与 UK Biobank 两个人群生物样本库。
  • 最终数据集共 640 092 人(Geisinger MyCode 170 503 人,UK Biobank 469 589 人),男性 280 958 人(43·9%),女性 359 134 人(56·1%)。
  • 从 27 个常染色体显性遗传基因和 1 个获得性疾病基因中,将携带常染色体显性致病/可能致病变异或 UBA1 体细胞致病/可能致病变异者归类为病例;对照为 28 个基因中无任何致病/可能致病变异者。
  • 变异按美国医学遗传学与基因组学学会指南分类并分为 tier 1 或 tier 2;在 tier 1 病例中评估外显率(≥1 个系统性自身炎症性疾病相关 ICD-10 编码组)和临床谱。
  • 使用 Fisher 精确检验计算比值比(OR),采用 Bonferroni-Holm 校正,两个队列分别分析。

主要发现

  • 共识别 159 例携带 17 个基因的罕见致病/可能致病变异者,Geisinger MyCode 患病率 0·04%(63/170 503),UK Biobank 0·02%(96/469 589),合并估计患病率为 1/4026(0·02%)。
  • 仅 1 例参与者有自身炎症性疾病诊断记录。
  • Geisinger MyCode 病例外显率为 79%(50/63),UK Biobank 为 32%(31/96),总体外显率 51%。
  • 81/159 例病例表现出多器官系统炎症特征,尤其肺部和皮肤表现,并观察到血管炎诊断(Geisinger MyCode OR 5·06 [1·01-15·54])和风湿性自身免疫性疾病诊断(Geisinger MyCode OR 2·29 [0·88-5·04];UK Biobank OR 12·28 [4·12-30·68])。
  • 病例较对照免疫抑制剂使用增加(Geisinger MyCode OR 3·98 [95% CI 1·40-9·23]),与临床相关疾病一致。

关键数值与推荐

  • 外显率定义为至少 1 个系统性自身炎症性疾病相关 ICD-10 编码组,在 tier 1 病例中评估。
  • 变异按美国医学遗传学与基因组学学会指南分类并分为 tier 1 或 tier 2。
  • 病例定义:携带 27 个常染色体显性遗传基因的致病/可能致病变异,或 UBA1 体细胞致病/可能致病变异。
  • 对照定义:28 个基因中无任何致病/可能致病变异。

临床怎么用

  • 对携带自身炎症性疾病相关基因致病/可能致病变异者,即使缺乏典型诊断记录,也应警惕多系统炎症表现并考虑遗传评估以指导治疗。
  • 临床遇到不明原因多系统炎症(尤其肺部、皮肤表现或血管炎)时,可考虑自身炎症性疾病基因检测。

局限性

  • 研究设计或实施未纳入有相关生活经验者的参与。
  • 两个队列外显率差异较大(Geisinger MyCode 79% vs UK Biobank 32%),可能反映队列特征或记录差异。
  • 仅基于 ICD-10 编码和免疫抑制剂使用评估临床谱,可能存在编码不完整或误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic autoinflammatory diseases are rare diseases caused by innate immune dysregulation and are often linked to single-gene variants. Diagnosis remains challenging due to incomplete penetrance and variable expressivity. This study aimed to quantify the prevalence, penetrance, and clinical spectrum of systemic autoinflammatory diseases associated with pathogenic or likely pathogenic variants in 28 genes. METHODS: This retrospective cohort study applied a genome-first approach to whole exome sequencing linked to electronic health records from Geisinger MyCode Community Health Initiative (USA) and the UK Biobank (UK). From a curated list of 27 dominantly inherited and one acquired disease gene, individuals with autosomal dominant pathogenic or likely pathogenic variants or somatic pathogenic or likely pathogenic variants of UBA1 were classified as cases. Variants were classified according to American College of Medical Genetics and Genomics guidelines and assigned to tier 1 or tier 2. Controls were participants without any pathogenic or likely pathogenic variant in the 28 genes. Penetrance (≥1 systemic autoinflammatory disease-associated ICD-10 code group) and clinical spectrum were assessed in tier 1 cases by comparing inflammatory ICD-10 codes and immunosuppressant use between cases and controls, with expressivity defined as the number of enriched ICD-10 code groups. Odds ratios (ORs) were calculated using Fisher's exact test with Bonferroni-Holm correction, and cohorts were analysed separately. There was no lived experience involvement in the study design or conduct. FINDINGS: The final dataset consisted of 640 092 participants (170 503 from Geisinger MyCode and 469 589 from the UK Biobank). 280 958 (43·9%) were male and 359 134 (56·1%) were female. We identified 159 individuals carrying rare pathogenic or likely pathogenic variants in 17 genes, corresponding to a prevalence of 0·04% (63 of 170 503) in Geisinger MyCode and 0·02% (96 of 469 589) in the UK Biobank with a combined estimated prevalence of one in 4026 individuals (0·02%). Only one participant had a documented diagnosis of an autoinflammatory disorder. Geisinger MyCode cases had a disease penetrance of 79% (50 of 63) compared with a disease penetrance of 32% (31 of 96) in the UK Biobank. Overall, disease penetrance was 51%, with 81 of 159 cases exhibiting inflammatory features across multiple organ systems, especially pulmonary and cutaneous manifestations, as well as diagnoses of vasculitis (Geisinger MyCode OR 5·06 [1·01-15·54]) and rheumatic autoimmune disorders (Geisinger MyCode OR 2·29 [0·88-5·04]; UK Biobank OR 12·28 [4·12-30·68]. We also observed increased use of immunosuppressive medications in cases compared to controls (Geisinger MyCode OR 3·98 [95% CI 1·40-9·23]) consistent with clinically relevant disease. INTERPRETATION: These findings suggest that monogenic autoinflammatory diseases are more common than currently recognised. Despite carrying disease-associated variants, almost no affected individuals had a documented systemic autoinflammatory disease diagnoses, pointing to a substantial gap in disease recognition and a missed opportunity to identify individuals with systemic inflammation who could benefit from genetic evaluation to guide therapy. FUNDING: Division of Cancer Epidemiology and Genetics, National Cancer Institute, the National Institutes of Health.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ercelen D, Anderson M, Kim J, et al. Genomic ascertainment of systemic autoinflammatory diseases: a retrospective cohort study in two population-based biobanks. Lancet Rheumatol. 2026. PMID: 42869051. doi:10.1016/S2665-9913(26)00217-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。